108 related articles for article (PubMed ID: 27193566)
1. Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II.
Stüber T; van Ewijk R; Diessner J; Kühn T; Flock F; Felberbaum R; Blettner M; Kreienberg R; Janni W; Wöckel A; Singer S; Schwentner L
Breast Cancer; 2017 Mar; 24(2):281-287. PubMed ID: 27193566
[TBL] [Abstract][Full Text] [Related]
2. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.
Schwentner L; Van Ewijk R; Kühn T; Flock F; Felberbaum R; Blettner M; Kreienberg R; Janni W; Wöckel A; Singer S
Support Care Cancer; 2016 Jun; 24(6):2759-66. PubMed ID: 26816089
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
4. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ
Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982
[TBL] [Abstract][Full Text] [Related]
5. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study.
Leinert E; Schwentner L; Blettner M; Wöckel A; Felberbaum R; Flock F; Kühn T; Denkinger MD; Janni W; Kreienberg R; Singer S;
Breast J; 2019 May; 25(3):386-392. PubMed ID: 30945393
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making.
Harder H; Ballinger R; Langridge C; Ring A; Fallowfield LJ
Psychooncology; 2013 Dec; 22(12):2729-35. PubMed ID: 23813806
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
Verschoor AM; Kuijer A; Verloop J; Van Gils CH; Sonke GS; Jager A; van Dalen T; Elias SG
Breast Cancer Res Treat; 2016 Sep; 159(2):357-65. PubMed ID: 27514397
[TBL] [Abstract][Full Text] [Related]
9. [Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study].
Wolters R; Wöckel A; Wischnewsky M; Kreienberg R
Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):468-75. PubMed ID: 21843852
[TBL] [Abstract][Full Text] [Related]
10. Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.
Ebner F; van Ewijk R; Wöckel A; Hancke K; Schwentner L; Fink V; Kreienberg R; Janni W; Blettner M
Breast; 2015 Jun; 24(3):256-62. PubMed ID: 25769974
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
12. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
13. The course of psychiatric co-morbidity in patients with breast cancer--results from the prospective multi-centre BRENDA II study.
Singer S; Schwentner L; van Ewijk R; Blettner M; Wöckel A; Kühn T; Felberbaum R; Flock F; Janni W;
Psychooncology; 2016 May; 25(5):590-6. PubMed ID: 26361249
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
15. [Trans-sectoral care for patients with colorectal cancer: Design of a prospective randomized controlled multi-center trial (FKZ 01GY1143)].
Landenberger M; Boese S; Fach EM; Bauer A
Z Evid Fortbild Qual Gesundhwes; 2015; 109(2):171-80. PubMed ID: 26028456
[TBL] [Abstract][Full Text] [Related]
16. Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Leinert E; Schwentner L; Janni W; Wöckel A; Herbert SL; Herr D; Kühn T; Flock F; Felberbaum R; Kreienberg R; Fink V; Dayan D; Ernst K; Singer S;
Breast Cancer; 2022 May; 29(3):429-436. PubMed ID: 35178667
[TBL] [Abstract][Full Text] [Related]
17. Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients.
Wollschläger D; Meng X; Wöckel A; Janni W; Kreienberg R; Blettner M; Schwentner L
Breast J; 2018 Mar; 24(2):120-127. PubMed ID: 28685896
[TBL] [Abstract][Full Text] [Related]
18. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.
Lindley C; Vasa S; Sawyer WT; Winer EP
J Clin Oncol; 1998 Apr; 16(4):1380-7. PubMed ID: 9552041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
